ACTINIUM PHARMACEUTICALS, INC. Increase Decrease In Operating Lease Liability
ACTINIUM PHARMACEUTICALS, INC. (ATNM) reported Increase Decrease In Operating Lease Liability of -$348.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-07
- ACTINIUM PHARMACEUTICALS, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$176.00K.
- ACTINIUM PHARMACEUTICALS, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$172.00K.
- ACTINIUM PHARMACEUTICALS, INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$154.00K.
- ACTINIUM PHARMACEUTICALS, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$145.00K.
- ACTINIUM PHARMACEUTICALS, INC. increase decrease in operating lease liability for fiscal 2025 was -$577.00K.
- ACTINIUM PHARMACEUTICALS, INC. increase decrease in operating lease liability for fiscal 2024 was -$530.00K.
- ACTINIUM PHARMACEUTICALS, INC. increase decrease in operating lease liability for fiscal 2023 was -$494.00K.
- ACTINIUM PHARMACEUTICALS, INC. increase decrease in operating lease liability for fiscal 2022 was -$272.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$176.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$348.00K 10-Q · filed 2026-08-07 | -$502.00K derived: sum of 3 quarters · filed 2026-08-07 | -$647.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | -$172.00K 10-Q · filed 2026-05-08 | -$326.00K derived: sum of 2 quarters · filed 2026-05-08 | -$471.00K derived: sum of 3 quarters · filed 2026-05-08 | -$611.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | -$154.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$299.00K derived: sum of 2 quarters · filed 2026-03-30 | -$439.00K derived: sum of 3 quarters · filed 2026-08-07 | -$577.00K 10-K · filed 2026-03-30 |
| 2025-09-30 | -$145.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$285.00K derived: sum of 2 quarters · filed 2026-08-07 | -$423.00K 10-Q · filed 2025-11-14 | -$559.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | -$140.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$278.00K 10-Q · filed 2026-08-07 | -$414.00K derived: sum of 3 quarters · filed 2026-08-07 | -$549.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | -$138.00K 10-Q · filed 2026-05-08 | -$274.00K derived: sum of 2 quarters · filed 2026-05-08 | -$409.00K derived: sum of 3 quarters · filed 2026-05-08 | -$539.00K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$136.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$271.00K derived: sum of 2 quarters · filed 2026-03-30 | -$401.00K derived: sum of 3 quarters · filed 2026-03-30 | -$530.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | -$135.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$265.00K derived: sum of 2 quarters · filed 2025-11-14 | -$394.00K 10-Q · filed 2025-11-14 | -$521.00K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$130.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | -$259.00K 10-Q · filed 2025-08-08 | -$386.00K derived: sum of 3 quarters · filed 2025-08-08 | -$511.00K derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | -$129.00K 10-Q · filed 2025-05-09 | -$256.00K derived: sum of 2 quarters · filed 2025-05-09 | -$381.00K derived: sum of 3 quarters · filed 2025-05-09 | -$503.00K derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | -$127.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$252.00K derived: sum of 2 quarters · filed 2025-03-31 | -$374.00K derived: sum of 3 quarters · filed 2025-03-31 | -$494.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | -$125.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$247.00K derived: sum of 2 quarters · filed 2024-11-14 | -$367.00K 10-Q · filed 2024-11-14 | -$386.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$122.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | -$242.00K 10-Q · filed 2024-08-05 | -$261.00K derived: sum of 3 quarters · filed 2024-08-05 | -$292.00K derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | -$120.00K 10-Q · filed 2024-04-26 | -$139.00K derived: sum of 2 quarters · filed 2024-04-26 | -$170.00K derived: sum of 3 quarters · filed 2024-04-26 | |
| 2022-12-31 | -$19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$50.00K derived: sum of 2 quarters · filed 2024-03-29 | -$272.00K 10-K · filed 2024-03-29 | |
| 2022-09-30 | -$31.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$253.00K 10-Q · filed 2023-11-02 | ||
| 2022-06-30 | -$222.00K 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |